Melphalan

Generic Name
Melphalan
Brand Names
Alkeran, Evomela, Phelinun, Pepaxti
Drug Type
Small Molecule
Chemical Formula
C13H18Cl2N2O2
CAS Number
148-82-3
Unique Ingredient Identifier
Q41OR9510P
Background

Melphalan is a nitrogen mustard or bischloroethylamine type alkylating agent. It was first synthesized in the early 1950s by substituting L-phenylalanine for the methyl group on nitrogen mustard. Melphalan is used in the treatment of multiple myeloma and ovarian carcinoma. It is also used for high-conditioning before hematopoietic stem cell transplant. It is also used to treat uveal melanoma with unresectable hepatic metastases.

Indication

Melphalan is indicated for use as a high-dose conditioning treatment prior to hematopoietic stem cell transplantation in patients with multiple myeloma. It is also indicated for the palliative treatment of multiple myeloma and for the palliation of non-resectable epithelial carcinoma of the ovary.

Melphalan is a component of HEPZATO KIT, a liver-directed therapy indicated for the treatment of adults with uveal melanoma with unresectable hepatic metastases affecting less than 50% of the liver and no extrahepatic disease or extrahepatic disease limited to the bone, lymph nodes, subcutaneous tissues, or lung that is amenable to resection or radiation.

Associated Conditions
Multiple Myeloma (MM), Unresectable Liver Metastasis, Unresectable Ovarian Cancer (Epithelial)
Associated Therapies
Conditioning regimens for allogeneic stem cell transplantation therapy
Clinical Trials
Related News

Bortezomib Followed by High-Dose Melphalan and Bortezomib as Conditioning Regimen for Tandem Stem Cell Transplants

First Posted Date
2006-03-27
Last Posted Date
2017-03-06
Lead Sponsor
H. Lee Moffitt Cancer Center and Research Institute
Target Recruit Count
30
Registration Number
NCT00307086
Locations
🇺🇸

H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States

Lenalidomide and Melphalan in Treating Patients With Previously Untreated Multiple Myeloma

First Posted Date
2006-03-22
Last Posted Date
2023-08-04
Lead Sponsor
NCIC Clinical Trials Group
Target Recruit Count
51
Registration Number
NCT00305812
Locations
🇨🇦

Allan Blair Cancer Centre at Pasqua Hospital, Regina, Saskatchewan, Canada

🇨🇦

Nova Scotia Cancer Centre, Halifax, Nova Scotia, Canada

🇨🇦

Hopital Notre-Dame du CHUM, Montreal, Quebec, Canada

and more 11 locations

Carboplatin, Melphalan, Etoposide Phosphate, Mannitol, and Sodium Thiosulfate in Treating Patients With Previously Treated Brain Tumors

First Posted Date
2006-03-17
Last Posted Date
2022-03-17
Lead Sponsor
OHSU Knight Cancer Institute
Target Recruit Count
33
Registration Number
NCT00303849
Locations
🇺🇸

University of Minnesota/Masonic Cancer Center, Minneapolis, Minnesota, United States

🇺🇸

OHSU Knight Cancer Institute, Portland, Oregon, United States

Donor Stem Cell Transplant Followed By Donor White Blood Cell Infusions in Treating Young Patients With Hematologic Cancer

Not Applicable
Terminated
Conditions
Lymphoma
Leukemia
First Posted Date
2006-03-13
Last Posted Date
2013-07-15
Lead Sponsor
University of California, San Francisco
Target Recruit Count
8
Registration Number
NCT00301860
Locations
🇺🇸

UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States

Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer

First Posted Date
2006-02-13
Last Posted Date
2017-11-29
Lead Sponsor
Masonic Cancer Center, University of Minnesota
Target Recruit Count
43
Registration Number
NCT00290628
Locations
🇺🇸

University of Minnesota Cancer Center, Minneapolis, Minnesota, United States

Treatment of Mantle Cell Lymphoma at Diagnosis for Patients Under 65 Years

First Posted Date
2006-02-02
Last Posted Date
2009-02-12
Lead Sponsor
French Innovative Leukemia Organisation
Target Recruit Count
39
Registration Number
NCT00285389
Locations
🇫🇷

Regional university hospital, Rennes, France

🇫🇷

REgional Hospital, Tours, France

Donor Stem Cell Transplant or Donor White Blood Cell Infusions in Treating Patients With Hematologic Cancer

First Posted Date
2006-01-25
Last Posted Date
2017-09-27
Lead Sponsor
OHSU Knight Cancer Institute
Target Recruit Count
200
Registration Number
NCT00281879
Locations
🇺🇸

OHSU Knight Cancer Institute, Portland, Oregon, United States

Combination Chemotherapy, Total-Body Irradiation, and Alemtuzumab in Treating Patients Undergoing an Autologous Stem Cell Transplant for Stage I, Stage II, Stage III, or Stage IV Chronic Lymphocytic Leukemia

Phase 2
Completed
Conditions
Chronic Lymphocytic Leukemia
First Posted Date
2006-01-13
Last Posted Date
2016-09-26
Lead Sponsor
German CLL Study Group
Target Recruit Count
30
Registration Number
NCT00276809
Locations
🇩🇪

Medizinische Hochschule Hannover, Hannover, Germany

🇩🇪

Universitatsklinikum Heidelberg, Heidelberg, Germany

🇩🇪

University Hospital Schleswig-Holstein - Kiel Campus, Kiel, Germany

and more 9 locations

Cyclophosphamide and Total Body Irradiation in Treating Patients Who Are Undergoing an Autologous Peripheral Stem Cell Transplant For Chronic Lymphocytic Leukemia

First Posted Date
2006-01-11
Last Posted Date
2018-05-11
Lead Sponsor
German CLL Study Group
Target Recruit Count
169
Registration Number
NCT00275015
Locations
🇩🇪

Charite - Universitaetsmedizin Berlin - Campus Benjamin Franklin, Berlin, Germany

🇩🇪

Robert Roessle Comprehensive Cancer Center at University of Berlin - Charite Campus Buch, Berlin, Germany

🇩🇪

Internistische Praxis - Trier, Trier, Germany

and more 50 locations

Autologous Stem Cell Transplant in Treating Patients With Progressive or Recurrent Hodgkin's Lymphoma

First Posted Date
2005-12-15
Last Posted Date
2013-11-20
Lead Sponsor
Case Comprehensive Cancer Center
Target Recruit Count
42
Registration Number
NCT00265889
Locations
🇺🇸

Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy